SCHEMBL24535293

SCHEMBL24535293

CN(C)C(=O)c1nn2c(c1F)CNCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30793133 0.85 CXCR4 (0.30)
SCHEMBL24535154 0.85 CXCR4 (0.30)
SCHEMBL24535158 0.84 CXCR4 (0.34)
SCHEMBL30793624 0.84
SCHEMBL26308681 0.84
Hydrochloric Acid SCHEMBL25333775 0.83 CXCR4 (0.33)
SCHEMBL30793445 0.82 MAP4K1 (0.32)
SCHEMBL30793845 0.82 TLR9 (0.31)
SCHEMBL30793718 0.81 PDE4A (0.36)
SCHEMBL25435460 0.81 PDE9A (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709729-A1 PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER Jazz Pharmaceuticals Ireland Ltd. (IE) 2026-03-18 EP disclosed
WO-2024236452-A1 PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER JAZZ PHARMACEUTICALS IRELAND LTD. (IE) 2024-11-21 WO disclosed
WO-2024051763-A1 QUINAZOLINE HETEROCYCLIC DERIVATIVE OF KRAS MUTATION INHIBITOR FOR TREATING CANCER 深圳福沃药业有限公司 2024-03-14 WO disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 EP disclosed
US-20220194961-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. 2022-06-23 US disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed